ClinicalTrials.Veeva

Menu
Perceptive Pharma Research | Victoria Gastroenterology logo

Perceptive Pharma Research | Victoria Gastroenterology

Research site

Site insights

Top conditions

Top treatments

Etrasimod
Risankizumab
Guselkumab
TAK-279
695501
Elafibranor
NX-13
TAK-062

Parent organization

This site is a part of Perceptive Pharma Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Site Coordinator

Verified by this site

Active trials

8 of 14 total trials

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: TAK-279

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical...

Enrolling
Ulcerative Colitis
Drug: TAK-279
Drug: Placebo

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

Trial sponsors

Takeda logo
AbbVie logo
A
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Boehringer Ingelheim logo
Genfit logo
L

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems